Catalyst Wire Dossier Catalyst Wire Dossier

Bivalirudin (Angiomax)

bivalirudin · The Medicines Company
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Bivalirudin (Angiomax), covering 2013-08-01 to 2014-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients [Phase 3]

See pricing